Lymphoma is a type of cancer that begins in lymphocytes — the white blood cells that play a vital role in the immune system. These cells are located in areas such as the lymph nodes, spleen, thymus, ...
Stage 4 diffuse large B-cell lymphoma (DLBCL) is a rapidly growing lymphoma affecting at least one other organ outside the lymphatic system. Cancer is the unusual growth and spread of cells within the ...
B-cell lymphoma is a type of cancer originating from abnormal growth and proliferation of B lymphocytes and can be divided into different sub-types including diffuse large B-cell lymphoma (DLBCL), ...
The FDA approved Epkinly in combination with other standard lymphoma drugs, rituximab + lenalidomide, for relapsed or ...
In mantle cell lymphoma (MCL), an aggressive form of B-cell non-Hodgkin lymphoma, TP53 mutations are known to affect patients’ prognosis—but questions remain. What does the heterogeneity of TP53 ...
How Does Zynlonta Work for B-Cell Lymphoma? Zynlonta is an antibody drug conjugate (ADC), which is a type of targeted cancer medicine. ADCs work as smart bombs to find cancer cells in the body that ...
Four symptoms may indicate a possible relapse of diffuse large B-cell lymphoma. Learn more about them and when to contact a doctor. A relapse of diffuse large B-cell lymphoma can cause a variety of ...
Abdominal/gastrointestinal complaints are the most prevalent initial symptoms in DLBCL, reported by 26% of patients. Peripheral lymphadenopathy and testicular tumors are associated with low-risk ...
What Is Marginal Zone Lymphoma? Marginal zone lymphoma (MZL) isn’t one disease. It’s a group of rare, slow-growing blood cancers. They’re known as non-Hodgkin lymphomas because they start in your ...
Despite the late-stage miss, analysts maintained confidence in the Epkinly program, with Truist Securities saying the result ...
In a recent study published in the journal Nature Immunology, researchers investigate the effects of microenvironment signals on selection in mucosal germinal centers and their role in the development ...